<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8303">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00841204</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-01115</org_study_id>
    <secondary_id>NCI-2009-01115</secondary_id>
    <secondary_id>UARIZ-08-0841-04</secondary_id>
    <secondary_id>CDR0000633938</secondary_id>
    <secondary_id>N01CN35158</secondary_id>
    <secondary_id>08-0841-04</secondary_id>
    <secondary_id>UAZ05-2-10</secondary_id>
    <secondary_id>P30CA023074</secondary_id>
    <nct_id>NCT00841204</nct_id>
  </id_info>
  <brief_title>Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma</brief_title>
  <official_title>Phase II Trial of Sulindac in Individuals at Increased Risk for Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial is studying how well sulindac works in preventing melanoma in
      healthy participants who are at increased risk of melanoma. Sulindac may stop the growth of
      tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known
      whether sulindac is more effective than a placebo in preventing melanoma in individuals with
      many moles and abnormal moles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To determine sulindac and metabolite levels in healthy participants with atypical nevi
      and benign nevus at increased risk for melanoma treated with sulindac versus placebo.

      SECONDARY OBJECTIVES:

      I. To assess the effects of sulindac on apoptosis in atypical nevi of these participants.

      II. To assess the effects of sulindac on VEGF expression in atypical nevi of these
      participants.

      III. To assess sulindac and metabolite levels in plasma and its association with drug levels
      in the target tissue.

      OUTLINE: This is a multicenter study. Participants are randomized to 1 of 2 treatment arms.

      ARM I: Participants receive oral sulindac twice daily.

      ARM II: Participants receive oral placebo twice daily.

      In both arms, treatment continues for 8 weeks in the absence of unacceptable toxicity.

      Blood and tissue samples are collected at baseline and/or after completion of study therapy
      and analyzed for sulindac and metabolite levels via high performance liquid chromatography
      tandem mass spectrometry; the detection of apoptotic cells via TUNEL assay; and VEGF
      expression via immunohistochemistry assays.

      After completion of study therapy, participants are followed for 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Sulindac Concentration in the Nevi (Moles)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Sulindac Sulfone, an Active Metabolite of Sulindac, Concentration in the Nevi</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Sulindac Sulfide, an Active Metabolite of Sulindac, Concentration in the Nevi</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sulindac Effects on Apoptosis in Atypical Nevi</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sulindac Effects on Vascular Endothelial Growth Factor (VEGF) Expression in Atypical Nevi</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association Between Plasma and Target Tissue Drug Levels</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive oral sulindac twice daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive oral placebo twice daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sulindac</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Aflodac</other_name>
    <other_name>Algocetil</other_name>
    <other_name>Clinoril</other_name>
    <other_name>SULIN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Inactive agent</description>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria:

          -  Healthy participants at risk for developing melanoma and meeting the following
             criteria: must have &gt;= 4 large (&gt;= 5 mm and &lt; 15 mm) atypical nevi and have 1 benign
             nevus amenable to biopsies

          -  No histologically confirmed melanoma on the baseline biopsy

          -  No more than 1 prior cutaneous melanoma

          -  One prior stage I, IIA, or IIB melanoma allowed provided patients have been off
             treatment &gt; 3 months

          -  Modified dermoscopy score &lt; 4.8

          -  Karnofsky performance status 80-100%

          -  ANC &gt;= 1,500/mm^3

          -  No family history of melanoma involving &gt;= 2 first degree relatives

          -  Platelets count &gt;= 100,000/mm^3

          -  Total bilirubin =&lt; 2.0 mg/dL

          -  AST/ALT =&lt; 2.0 times upper limit of normal

          -  Creatinine =&lt; 1.5 mg/dL

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  More than 6 months since prior and no concurrent tanning bed use or other methods to
             promote sun-tanning

          -  Willing to minimize sunlight exposure by applying sunscreen/sunblock or wearing
             clothing to shield skin during outdoor activity during study participation

          -  Willing or able to limit alcohol consumption to less than 3 servings a week during
             the study period

          -  No frequent, chronic or moderate/severe gastrointestinal (GI) complaints

          -  Upper GI problems requiring prescription or nonprescription medical remedies for
             symptoms of heartburn, dyspepsia, nausea, or abdominal pain &gt; once a week on average

          -  History of peptic ulcer, occult or gross intestinal bleeding

          -  No prior allergic reaction to aspirin (unless subsequent dosing with other NSAIDs has
             been well tolerated)

          -  No history of allergic reaction to lidocaine or xylocaine

          -  No history of allergic reaction (e.g., urticaria, asthma, or rhinitis) or gastric
             intolerance attributed to compounds of similar chemical or biological composition to
             sulindac

          -  No invasive cancer or cancer treatment within the past 5 years, except nonmelanoma
             skin cancer

          -  No immunosuppression by medication or disease, including any of the following: AIDS,
             oral prednisone, immunosuppressant/immunomodulator (i.e., cyclosporine,
             chemotherapeutic agent, or biologic therapy)

          -  No uncontrolled intercurrent illness

          -  No ongoing or active infection

          -  No symptomatic congestive heart failure

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

          -  No psychiatric illness/social situations that would limit compliance with study
             requirements

          -  At least 30 days since prior participation and no concurrent enrollment or planning
             to enroll in another clinical trial

          -  No NSAIDs for more than 5 days per month within the past 3 months and no concurrent
             non-study NSAIDs, except low dose aspirin (81 mg/day)

          -  Willing or able to refrain from herbal medicines, above-standard vitamins, or
             minerals during study

          -  Standard daily multivitamin/mineral supplement (i.e., therapeutic doses of calcium
             and vitamin D for osteoporosis) allowed

          -  No concurrent lithium, phenytoin, or sulfonamides

          -  WBC &gt;= 3,000/mm^3

          -  No history of bleeding or clotting disorder

          -  At least 3 months since prior and no concurrent coumadin or other systemic
             anticoagulant other than aspirin
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hsiao-Hui (Sherry) Chow</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona Health Sciences Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona Health Sciences Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Hospitals and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>February 10, 2009</firstreceived_date>
  <firstreceived_results_date>February 14, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sulindac</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sulindac</title>
          <description>Participants receive oral sulindac twice daily for 8 weeks in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants receive oral placebo twice daily for 8 weeks in the absence of unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sulindac</title>
          <description>Participants receive oral sulindac twice daily for 8 weeks in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants receive oral placebo twice daily for 8 weeks in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="50"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="50"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="46.2" spread="10.0"/>
                <measurement group_id="B2" value="45.9" spread="8.59"/>
                <measurement group_id="B3" value="46.0" spread="9.24"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="22"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="28"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="50"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Sulindac Effects on Apoptosis in Atypical Nevi</title>
        <time_frame>8 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sulindac Effects on Vascular Endothelial Growth Factor (VEGF) Expression in Atypical Nevi</title>
        <time_frame>8 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association Between Plasma and Target Tissue Drug Levels</title>
        <time_frame>8 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sulindac Concentration in the Nevi (Moles)</title>
        <time_frame>8 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>All randomized participants were included in the analysis except one participant in the sulindac arm did not provide nevi sample for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Sulindac</title>
            <description>Participants receive oral sulindac twice daily for 8 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants receive oral placebo twice daily for 8 weeks in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Sulindac Concentration in the Nevi (Moles)</title>
            <units>µg/g tissue</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.51" spread="1.05"/>
                  <measurement group_id="O2" value="0" spread="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sulindac Sulfone, an Active Metabolite of Sulindac, Concentration in the Nevi</title>
        <time_frame>8 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>All randomized participants were included in the analysis except one participant in the sulindac arm did not provide nevi sample for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Sulindac</title>
            <description>Participants receive oral sulindac twice daily for 8 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants receive oral placebo twice daily for 8 weeks in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Sulindac Sulfone, an Active Metabolite of Sulindac, Concentration in the Nevi</title>
            <units>µg/g tissue</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.38" spread="2.86"/>
                  <measurement group_id="O2" value="0" spread="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sulindac Sulfide, an Active Metabolite of Sulindac, Concentration in the Nevi</title>
        <time_frame>8 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>All randomized participants were included in the analysis except one participant in the sulindac arm did not provide nevi sample for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Sulindac</title>
            <description>Participants receive oral sulindac twice daily for 8 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants receive oral placebo twice daily for 8 weeks in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Sulindac Sulfide, an Active Metabolite of Sulindac, Concentration in the Nevi</title>
            <units>µg/g tissue</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.12" spread="0.12"/>
                  <measurement group_id="O2" value="0" spread="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sulindac</title>
          <description>Participants receive oral sulindac twice daily for 8 weeks in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants receive oral placebo twice daily for 8 weeks in the absence of unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Vasovagal episode</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Flu-like syndromes</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Other pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Other infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Extremity/Limb pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Muscle pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterus pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal/Paranasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Larynx/Pharynx/Throat pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Prutitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Other skin disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Skin pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>H-H. Sherry Chow, Ph.D.</name_or_title>
      <organization>The University of Arizona</organization>
      <phone>520-626-3358</phone>
      <email>schow@azcc.arizona.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
